LTE-1 ASPEN LTFU

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Dr. Shirley D’Sa highlights the 5.8-year follow-up results from the ASPEN long-term extension study, demonstrating the durable efficacy, deepening responses, and favorable safety profile of zanubrutinib in patients with Waldenström macroglobulinemia, including those with high-risk genetic mutations.

Long-term clinical outcomes in patients with Waldenström macroglobulinemia (WM) who received zanubrutinib in the phase 3 ASPEN study: A report from the zanubrutinib extension study